Swiss CDMO to expand newly bought Glycotope biomanufacturing plant in Germany

By Dan Stanton contact

- Last updated on GMT

The facility is in Heidelberg, Germany. GettyImages/Jan-Schneckenhaus
The facility is in Heidelberg, Germany. GettyImages/Jan-Schneckenhaus

Related tags: Biotechnology

Celonic says it will immediately begin expanding the former Glycotope site in Heidelberg, Germany adding two 2,000L single-use bioreactors.

“Glycotope Biotechnology GmbH business operations in Heidelberg, with all its tangible and intangible operating assets, are being acquired by Celonic AG,”​ Vikalp Mohan, Celonic VP of Global Commercial Operations at Swiss contract development and manufacturing organisation (CDMO) Celonic, told Biopharma-Reporter.

“It’s an all- cash assets deal,”​ he said, though further financial details were not disclosed.

The site consists of five GMP biomanufacturing suites equipped with varying operational capacity of up-to 1,000L single-use bioreactors, he continued, adding Celonic is set on increasing capacity going forward.

“We will be immediately initiating work on expanding capacity with two new modular-expandable clean rooms with 2,000L single-use bioreactors each [a total of two], with plans to keep adding similar scale capacity in future.”

Around 120 staff working at Heidelberg will be kept on by Celonic, which will also manufacture for Glycotope at the site, However, Mohan said his firm’s “core business model continues to be serving bio-pharmaceutical customers, beyond Glycotope.”

The CDMO will also add Glycotope’s GEX human cell line platform to its own CHOvolution development platform, offering customers what it says is a “unique opportunity”​ to select a tailored expression system suitable for their biotherapeutic development needs.

The GEX platform offers clients glyco-optimization and high yield production of a variety of fully human glycosylated biopharmaceuticals, and by using a range of glyco-engineered proprietary human cell lines aimed at optimising a series of different determining sugars.

Related news

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more